Exploring new treatments for aggressive lung and prostate cancers
Official title: Characterizing the theranostic potential of DLL3-targeting agents in high-grade neuroendocrine carcinomas of the lung and prostate
Funded at Sloan-Kettering Inst Can Research · NIH-10980038 · Data updated 2026-11-12
This study is looking at a new treatment for people with small cell lung cancer and neuroendocrine prostate cancer by targeting a protein called DLL3, hoping to improve how these tough cancers are diagnosed and treated.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 2, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $704,422 |
| NIH project number | 1R01CA286918-01A1 |
| Project ID | NIH-10980038 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with small cell lung cancer or neuroendocrine prostate cancer.
✕Less likely to help
Patients with other types of cancer or those who do not have high-grade neuroendocrine carcinomas may not benefit from this research.
What this research studies
This research focuses on small cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC), both of which are aggressive forms of cancer that often do not respond well to existing treatments. The study aims to develop and test a new type of therapy that targets a specific protein called DLL3, which is found on the surface of cancer cells. By using a specially designed antibody that can both diagnose and treat these cancers through imaging techniques, the research seeks to improve outcomes for patients with these challenging conditions.
Why it matters
Potential benefit: If successful, this research could lead to more effective diagnostic and therapeutic options for patients suffering from high-grade neuroendocrine carcinomas.
How similar studies have gone: Previous research has shown promise in targeting DLL3 in similar cancer types, indicating a potential for success in this novel approach.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Bodei, Lisa — Sloan-Kettering Inst Can Research
- Study coordinator: Bodei, Lisa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.